309 related articles for article (PubMed ID: 29777573)
1. Quantiferon-Cytomegalovirus assay: A potentially useful tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell transplant patients.
Paouri B; Soldatou A; Petrakou E; Theodosaki M; Tsentidis C; Kaisari K; Oikonomopoulou C; Matsas M; Goussetis E
Pediatr Transplant; 2018 Aug; 22(5):e13220. PubMed ID: 29777573
[TBL] [Abstract][Full Text] [Related]
2. Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR.
Krawczyk A; Ackermann J; Goitowski B; Trenschel R; Ditschkowski M; Timm J; Ottinger H; Beelen DW; Grüner N; Fiedler M
J Clin Virol; 2018; 99-100():61-66. PubMed ID: 29331844
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
Fleming T; Dunne J; Crowley B
J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
[TBL] [Abstract][Full Text] [Related]
5. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications.
Tey SK; Kennedy GA; Cromer D; Davenport MP; Walker S; Jones LI; Crough T; Durrant ST; Morton JA; Butler JP; Misra AK; Hill GR; Khanna R
PLoS One; 2013; 8(10):e74744. PubMed ID: 24146744
[TBL] [Abstract][Full Text] [Related]
6. Clinical Usefulness of Monitoring Cytomegalovirus-Specific Immunity by Quantiferon-CMV in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Lee SM; Kim YJ; Yoo KH; Sung KW; Koo HH; Kang ES
Ann Lab Med; 2017 May; 37(3):277-281. PubMed ID: 28224776
[TBL] [Abstract][Full Text] [Related]
7. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients.
Barron MA; Gao D; Springer KL; Patterson JA; Brunvand MW; McSweeney PA; Zeng C; Barón AE; Weinberg A
Clin Infect Dis; 2009 Dec; 49(12):1777-83. PubMed ID: 19911937
[TBL] [Abstract][Full Text] [Related]
8. Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation.
Yong MK; Cameron PU; Slavin M; Morrissey CO; Bergin K; Spencer A; Ritchie D; Cheng AC; Samri A; Carcelain G; Autran B; Lewin SR
J Infect Dis; 2017 Jun; 215(11):1684-1694. PubMed ID: 28431019
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR
Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286
[TBL] [Abstract][Full Text] [Related]
10. Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
Seo E; Choi ES; Kim JH; Kim H; Koh KN; Im HJ; Lee J
PLoS One; 2021; 16(2):e0246191. PubMed ID: 33544726
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series.
Andreani M; Albano L; Benzaken S; Cassuto E; Jeribi A; Caramella A; Giordanengo V; Bernard G; Esnault V; Seitz-Polski B
Transplant Proc; 2020; 52(1):204-211. PubMed ID: 31889538
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients.
Wu JL; Ma HY; Lu CY; Chen JM; Lee PI; Jou ST; Yang YL; Chang HH; Lu MY; Chang LY; Huang LM
J Microbiol Immunol Infect; 2017 Jun; 50(3):307-313. PubMed ID: 26346369
[TBL] [Abstract][Full Text] [Related]
13. Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation.
Liu J; Chang YJ; Yan CH; Xu LP; Jiang ZF; Zhang XH; Liu KY; Huang XJ
J Infect; 2016 Sep; 73(3):261-70. PubMed ID: 27311748
[TBL] [Abstract][Full Text] [Related]
14. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
[TBL] [Abstract][Full Text] [Related]
15. The potential association of CMV-specific CD8+ T lymphocyte reconstitution with the risk of CMV reactivation and persistency in post allogeneic stem cell transplant patients.
Shams El-Din AA; El-Desoukey NA; Amin Tawadrous DG; Fouad NMBE; Abdel-Mooti M; Hotar SF
Hematology; 2018 Sep; 23(8):463-469. PubMed ID: 29313439
[TBL] [Abstract][Full Text] [Related]
16. Frequent occurrence of cytomegalovirus retinitis during immune reconstitution warrants regular ophthalmic screening in high-risk pediatric allogeneic hematopoietic stem cell transplant recipients.
Hiwarkar P; Gajdosova E; Qasim W; Worth A; Breuer J; Chiesa R; Ridout D; Edelsten C; Moore A; Amrolia P; Veys P; Rao K
Clin Infect Dis; 2014 Jun; 58(12):1700-6. PubMed ID: 24700657
[TBL] [Abstract][Full Text] [Related]
17. Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients.
Ciáurriz M; Beloki L; Zabalza A; Bandrés E; Mansilla C; Pérez-Valderrama E; Lachén M; Rodríguez-Calvillo M; Ramírez N; Olavarría E
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921749
[TBL] [Abstract][Full Text] [Related]
18. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia.
Lisboa LF; Kumar D; Wilson LE; Humar A
Transplantation; 2012 Jan; 93(2):195-200. PubMed ID: 22179399
[TBL] [Abstract][Full Text] [Related]
20. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients.
Camacho-Bydume C; Mauguen A; Rodriguez-Sanchez MI; Klein E; Kernan NA; Prockop S; Boelens JJ; Papanicolaou GA; Cancio M
Cytotherapy; 2022 Apr; 24(4):428-436. PubMed ID: 35042670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
